Metabolic research
Reta / Cagri Blend
Reta (5mg) and Cagri (5mg) in a single vial: a triple-receptor agonist paired with a long-acting amylin analog. Freeze-dried, ≥99% per component.
Save up to 30% on Reta / Cagri Blend.
Stack it with Tirz or Reta to unlock the savings.
20%
+1 peptide
25%
+2 peptides
30%
+3 or more
For research and educational purposes only. PepTalk discusses what researchers study in laboratory settings, not medical advice. Products are sold for laboratory research use only.
The short version
This blend combines two of the most-watched compounds in metabolic research. Reta acts on three receptors at once (GIP, GLP-1 and glucagon). Cagri is a long-acting version of amylin, a separate fullness signal. Pairing an incretin-based compound with an amylin analog is one of the most active areas in current metabolic research.
What researchers are looking at
Reta is a triple-receptor agonist. Two of its pathways, GIP and GLP-1, are studied for reducing hunger signaling and improving how the body handles insulin. The third, glucagon, is studied for raising energy expenditure and mobilizing fat stored in the liver.
Cagri works through a completely different system. Amylin is a hormone released alongside insulin after a meal, and it signals fullness through its own receptors in the brain. Natural amylin breaks down quickly; Cagri is a long-acting analog built to last much longer, so researchers can study sustained amylin signaling.
Because the two compounds act on separate pathways, combining them lets researchers study whether incretin and amylin signals add to each other. Each compound has been studied on its own in human clinical research, while this specific two-in-one combination is a newer research area.
Three receptors
Reta acts at GIP, GLP-1 and glucagon receptors, studied for appetite, insulin handling and energy expenditure.
A separate fullness signal
Cagri is a long-acting amylin analog, studied for satiety signaling through its own receptors in the brain.
Studied together
Researchers combine them to ask whether incretin and amylin signals add to each other.
Where the evidence stands
an honest mapBoth components well characterized in metabolic models
Each studied individually in human trials; the combination is newer
At a glance
What it is
A two-compound blend
Reta 5mg + Cagri 5mg
Studied for
Appetite and energy use
metabolic research
Pathways
Four in total
GIP, GLP-1, glucagon, amylin
Research stage
Components in human trials
combination is newer
How it arrives
Lyophilized powder
Ships freeze-dried in a single vial. Before research use, it's reconstituted with bacteriostatic water. Once reconstituted, keep it refrigerated and use within the window noted on the Certificate of Analysis.
Bacteriostatic water
Needed to reconstitute
Certificate of analysis
Common questions
They work through different systems. Reta acts on the GIP, GLP-1 and glucagon receptors, while Cagri acts on amylin receptors. Combining them lets researchers study whether those signals add to each other.
For laboratory and research use only. Sold exclusively for in-vitro research and laboratory experimentation. Not a drug, supplement, or article intended for human or veterinary use; nothing here is medical advice or a claim of therapeutic benefit. Statements describe findings from published research.
Your Reliable Source for High-Quality Research Peptides
FastPeps is more than just a trusted U.S. supplier of research peptides. We are a catalyst for scientific advancement, dedicated to providing the highest quality peptides that empower our clients to push the boundaries of research.
